Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab
Innate Pharma is suffering through its second big setback of the year on its lead cancer drug lirilumab. Back in February the French biotech was forced to concede that lirilumab was no better than a placebo in fighting acute myeloid leukemia. And just before Thanksgiving researchers conceded that the drug combined with Bristol-Myers Squibb’s Opdivo (nivolumab) also flopped, this time in a study focused on squamous cell carcinoma of the head and neck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
